Clinical Trials Logo

Nasopharyngeal Neoplasms clinical trials

View clinical trials related to Nasopharyngeal Neoplasms.

Filter by:

NCT ID: NCT03942380 Recruiting - Clinical trials for Head and Neck Cancer

Cell-free Tumor DNA in Head and Neck Cancer Patients

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

This study investigates if head and neck squamous cell carcinoma can be tracked with cell-free tumor DNA, RNA or HPV-DNA, in blood samples from patients referred with suspicion of cancer, and if it can be used in detecting recurrence in patients already diagnosed and treated for head and neck squamous cell carcinoma.

NCT ID: NCT03924986 Active, not recruiting - Clinical trials for Recurrent or Metastatic Nasopharyngeal Cancer

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Start date: April 18, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase 3, Multicenter, Double-Blind, Randomized, Placebo-controlled Study to Compare the Efficacy and Safety of Tislelizumab (BGB-A317) Combined With Gemcitabine Plus Cisplatin Versus Placebo Combined With Gemcitabine Plus Cisplatin as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer.

NCT ID: NCT03890185 Active, not recruiting - Clinical trials for Nasopharyngeal Cancer

Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC

Start date: October 1, 2012
Phase: Phase 2
Study type: Interventional

The central hypothesis is to test Low Dose Fraction Radiotherapy (LDFRT), as a potentiator of Docetaxel and Cisplatin efficacy in locally advanced nasopharyngeal cancer.

NCT ID: NCT03854838 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

Start date: May 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of intensity-modulated radiation therapy combined with toripalimab in patients with the unresectable locally recurrent nasopharyngeal carcinoma.

NCT ID: NCT03847532 Recruiting - Clinical trials for MutYH-associated Polyposis

MUTYH-associated Polyposis

MAP
Start date: October 10, 2018
Phase: N/A
Study type: Interventional

This is single-center, prospective, non-randomized study

NCT ID: NCT03840421 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Start date: April 3, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the survival and toxicity of GP (gemcitabine and cisplatin) vs. PF (cisplatin and fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for locoregionally advanced nasopharyngeal carcinoma( NPC ) patients.

NCT ID: NCT03839602 Completed - Clinical trials for Intensity Modulated Radiation Therapy

Delineation of Reducing Clinical Target Volume for Early-stage Nasopharyngeal Carcinoma Patients

Start date: May 1, 2001
Phase: Phase 2
Study type: Interventional

To analyze the long-term results and toxicities of the reducing clinical target volume (CTV) delineation method in early-stage nasopharyngeal carcinoma (NPC) patients treated with intensity modulated radiation therapy (IMRT).

NCT ID: NCT03837808 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Start date: April 11, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase III trial to study the effectiveness of nimotuzumab versus cisplatin combined with intensity-modulated radiation therapy (IMRT) in treating patients with stage II-III nasopharyngeal carcinoma.

NCT ID: NCT03813394 Not yet recruiting - Clinical trials for Metastatic Nasopharyngeal Cancer

Bevacizumab and Pembrolizumab Combination in EBER-ISH Positive NPC

2018/00947
Start date: May 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic nasopharyngeal carcinoma (NPC).

NCT ID: NCT03810274 Completed - Clinical trials for Nasopharyngeal Carcinoma

3DV+TPS Software Outlines the Radiotherapy of Nasopharyngeal Carcinoma

Start date: February 1, 2012
Phase:
Study type: Observational

Comparing the accuracy and speed of 3DV+TPS software with imported TPS and domestic TPS to outline the contours of crisis organs, it is proved that 3DV+TPS has superiority compared with domestic TPS, and it has non-inferiority compared with imported TPS, indicating that the software can improve contour sketching accuracy. And speed, reduce the burden on doctors, improve medical efficiency.